Quarterly Report Q3 2018: DiaMedica Therapeutics reports improvement in Loss Corporate Wire Date: 17 January 2019 02:59 EST
DiaMedica Therapeutics (TSXV:DMA) announced loss for the quarter-ended 30 September 2018 of $US528,571, an improvement from $US3.6m in the previous corresponding period.
ACTIVITIES: DiaMedica Therapeutics Inc., previously Diamedica Inc is a development stage biopharmaceutical company. The Company is engaged in the discovery and development of drugs for the treatment of diabetes and related diseases.
DiaMedica Therapeutics Inc. (TSXV:DMA...